Sebastien Maloveste
Corporate Officer/Principal bei NEXTCURE, INC.
Profil
Sebastien Maloveste is currently working as the Senior Vice President-Business Development at NextCure, Inc. Previously, he held positions as the Director-Business Development at GenVec, Inc. and as the Associate Director-Business Development at Amplimmune, Inc. Dr. Maloveste obtained a doctorate degree from Universite De La Mediterranee.
Aktive Positionen von Sebastien Maloveste
| Unternehmen | Position | Beginn |
|---|---|---|
| NEXTCURE, INC. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Sebastien Maloveste
| Unternehmen | Position | Ende |
|---|---|---|
Amplimmune, Inc.
 Amplimmune, Inc. BiotechnologyHealth Technology Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | - |
| GENVEC INC | Corporate Officer/Principal | - |
Ausbildung von Sebastien Maloveste
| Universite De La Mediterranee | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| NEXTCURE, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
GenVec, Inc.
 GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |
Amplimmune, Inc.
Amplimmune, Inc. BiotechnologyHealth Technology Amplimmune, Inc. develops immune-based biological treatment for cancer and autoimmune diseases. The company was founded by Michael Richman, Charles G. Drake, Andrea Cox, Drew M. Pardoll, Jonathan D. Powell, Lieping Chen, David S. Kabakoff, and Elizabeth Jaffee in 2007 and is headquartered in Gaithersburg, MD. | Health Technology |
